Conception, Construction, Pre-Clinical & Clinical Testing of COH04S1 Vaccine with Activity Against SARS-CoV-2
Time: 12:00 pm
day: Day Two
Details:
- COVID-19 variants have arisen with different biologic properties culminating in the most recent and frightening variety referred to as Omicron. Development of a vaccine that would have prophylactic activity against a variety of SARS-CoV-2 strains by expanding the antigen cargo two
include both the Nucleocapsid and Spike antigens - Describing the development process of a vaccine including a proprietary synthetic viral platform, laboratory and animal studies, culminating with an overview of ongoing and completed Phase 1 and Phase 2 trials in healthy adults and immunocompromised cancer patients and stem cell
transplant recipients - Sharing results from Phase 1b trial (NCT046339466) and ongoing Phase 2 trials (NCT04977024) to demonstrate the capacity of a vaccine to stimulate protective humoral and cellular immunity in healthy persons and cancer patients
